Belgian research is distinguished by its continuity and excellence. For more than 30 years, the Fondation Charcot Stichting has been fighting with university research teams in Belgium for a better understanding of multiple sclerosis and to improve its treatments. More than ever, fundamental research is needed.
Multiple sclerosis (MS) is one of the most common chronic neurological disorders among young adults worldwide. In Belgium, it is estimated that more than 13,500 inhabitants suffer from this still incurable disease. MS can occur at any age, but the first symptoms usually appear between the ages of 20 and 40. For reasons that are still unclear, women are affected 2 to 3 times more often than men.
From incurable to controllable
Thirty years ago, treatment for multiple sclerosis was very limited and, if it was available at all, very often accompanied by side effects that were too severe. Research has made it possible to develop concrete treatments for some of the different forms of this disease. Treatments that are less invasive, more effective and that inhibit the development of MS. In order to continue these positive developments, basic research is essential.
Innovation and concrete results
In its collaboration with researchers, the Charcot Foundation has two objectives.
Innovation, because basic research must be revolutionary. Basic research is the only way to achieve better treatments. Today more than ever, it is necessary to promote this basic research in MS, interuniversity, interdisciplinary, with a global approach to the disease. Every door that closes or opens in current research leads to avenues where researchers can find treatments that benefit patients, whether they have MS or another disease. With this in mind, for MS, the path to remyelination - the process by which protective cells are rebuilt around a nerve to make it work again - is open.
The second objective is the need to achieve concrete results. This down-to-earth approach also means supporting research that directly improves patient comfort. Such as developing a different method of drug delivery that could significantly improve the effectiveness of the drug while being less invasive. Prevention and patient-specific treatments are also on the horizon.
Action, not just talk.
With 500,000 euros*, the Fondation Charcot Stichting is providing the essential resources to 10 teams of experienced researchers in neurology, neuroimmunology, neurobiology and rehabilitation sciences to ensure innovative and concrete advances in multiple sclerosis research.
(*) The winners were announced at an academic session of the Charcot Foundation on 23 January 2020. The funds allocated come entirely from private donations. The Charcot Foundation can issue tax certificates and is a member of Donorinfo.be and the Belgian Federation of Philanthropic Foundations.
